Clinical Trial Update: IMPACT-AML: Randomized Pragmatic Clinical Trial for Relapsed or Refractory AML [Phase 3]

View source ↗

Summary

IMPACT-AML is a Phase 3 randomized pragmatic trial evaluating treatment strategies for relapsed or refractory acute myeloid leukemia and is currently recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Snippet

Sponsor: National Research Center for Hematology, Russia | Conditions: Refractory Acute Myeloid Leukemia, Early Relapses of Acute Myeloid Leukemia | Phase 3 | Status: RECRUITING